Brief: Vicore Pharma Holding: Positive Data From Phase II Study Attract In Patients With COVID-19 Published Online

Vicore Pharma Holding AB

01/02/2021 07:04

Feb 1 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * VICORE PHARMA HOLDING AB: POSITIVE DATA FROM PHASE II
STUDY
ATTRACT IN PATIENTS WITH COVID-19 PUBLISHED ONLINE
    * PUBLISHED DATA FROM PHASE II STUDY ATTRACT ONLINE AND
SUBMITTED
IT TO A PEER REVIEWED JOURNAL
    * RESULTS SHOW RESTORATION OF LUNG FUNCTION IN COVID-19 ON
TOP OF
CORTICOSTEROIDS AND REMDESIVIR WITH COMPANY'S ORAL DRUG C21,
SUGGESTING THAT C21 CAN BECOME AN IMPORTANT COMPLEMENT TO
VACCINES TO COMBAT COVID-19 PANDEMIC.
    * ANGIOTENSIN II TYPE 2 RECEPTOR (AT2R) AGONIST C21 SHOWED
RESTORATION OF RESPIRATORY FUNCTION WITH A SIGNIFICANTLY LOWER
RISK OF BEING ON SUPPLEMENTAL OXYGEN AT END OF TREATMENT AND
DURING FOLLOW UP.

Source text: [ID:https://bit.ly/2MITMGG]
Further company coverage:  VICOR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))